HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Thomas A. Orszulak Hartzell V. Schaff Francisco J. Puga Gordon K. Danielson Charles J. Mullany Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Orszulak, T. A. Articles by Ilstrup, D. M. Search for Related Content PubMed PubMed Citation Articles by Orszulak, T. A. Articles by Ilstrup, D. M.

Ann Thorac Surg 1997;63:620-626
© 1997 The Society of Thoracic Surgeons

---

Original Article: Cardiovascular

Event Status of the Starr-Edwards Aortic Valve to 20 Years: A Benchmark for Comparison

Division of Thoracic and Cardiovascular Surgery and Section of Biostatistics, Mayo Clinic, Mayo Foundation, Rochester, Minnesota

Accepted for publication December 27, 1996.

Background. Considerable effort and expense has been invested in the evolutionary development of cardiac valvular prostheses with the goal of reducing or minimizing specific events related to these prostheses. It is important to measure any improvement achieved with such development by comparison against a historic standard. The Starr-Edwards caged-ball prosthesis model 1260 has been used for 30 years as the predominant or sole model of its kind for aortic valve replacement. This historic opportunity provides a benchmark for subsequent improvement and comparison of current prostheses.

Methods. Between 1969 and 1991, 1,100 patients (median age, 57 years; 838 men and 194 women) underwent aortic valve replacement with or without coronary artery bypass grafting (aortic valve replacement, 964; aortic valve replacement plus coronary artery bypass grafting, 136) with the 1260 Starr-Edwards caged-ball prosthesis.

Results. Operative mortality was 6.2% (68 patients). Univariate patient characteristics predictive of early mortality were female sex (p = 0.003), age (>56 years; p = 0.002), recent operative interval (1985 to 1991 versus 1969 to 1976 or 1977 to 1984;p = 0.002), presence of atrial fibrillation (p = 0.001), and small valve size (7A to 8A = 19 to 21 mm; p < 0.001). Follow-up extended to 11,293 patient-years (mean, 24.8 years) and was 96.9% complete. Survival at 5, 10, 15, and 20 years for all patients including operative mortality was 76.6%, 59.6%, 44.9%, and 31.2%, respectively. Operative variables predictive of poor late survival were advanced New York Heart Association class (III or IV); (p = 0.0001), older age (>56 years; p = 0.0001), and lower (<0.56) ejection fraction (p = 0.0001). Freedom from thromboemboli and anticoagulant-related bleeding at 5 years was 90.8% and 98.7%, respectively. Univariate model for greater risk of late thromboemboli identified female sex (p = 0.04), older age (>56 years; p = 0.0002), and New York Heart Association class III or IV (p = 0.0058), as risk factors. Multivariate analysis for thromboemboli demonstrated older age (p = 0.0007) and New York Heart Association class III or IV (p = 0.0041) as significant. Alternatively, univariate analysis for late bleeding found only the most recent operative interval (p = 0.009) as significant, and the rarity of events prevented a multivariate query. There were no valve failures.

Conclusions. The late results of survival and freedom from late anticoagulant-related bleeding or thromboemboli are excellent, especially in larger (9A and above) sizes, and with the long implant record comparable with more recent prostheses, the Starr-Edwards valve provides an excellent, safe, and durable alternative in the aortic position and provides a benchmark against which to compare other prostheses.

This article has been cited by other articles:

				A. Vahanian, B. Iung, L. Piérard, R. Dion, and J. Pepper CHAPTER 21 Valvular Heart Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				L. Lau, W.R. E. Jamieson, C. Hughes, E. Germann, and F. Chan What Prosthesis Should Be Used at Valve Re-Replacement After Structural Valve Deterioration of a Bioprosthesis? Ann. Thorac. Surg., December 1, 2006; 82(6): 2123 - 2132. [Abstract] [Full Text] [PDF]

				S. H. Rahimtoola Choice of prosthetic heart valve for adult patients J. Am. Coll. Cardiol., March 19, 2003; 41(6): 893 - 904. [Abstract] [Full Text] [PDF]

				J. Babin-Ebell, C. Schuster, O. Elert, R. Bergemann, D. Horstkotte, and GELIA Study Group Influence of valve size on morbidity and mortality for patients with mechanical valve replacements (GELIA 8) Eur. Heart J. Suppl., December 1, 2001; 3(suppl_Q): Q73 - Q77. [Abstract] [PDF]

				F. P. Casselman, M. L. Bots, W. Van Lommel, P. J. Knaepen, R. Lensen, and F. E.E. Vermeulen Repeated thromboembolic and bleeding events after mechanical aortic valve replacement Ann. Thorac. Surg., April 1, 2001; 71(4): 1172 - 1180. [Abstract] [Full Text] [PDF]

				O. Lund, H. K. Pilegaard, L. B. Ilkjaer, S. L. Nielsen, and H. Arildsen Performance profile of the Starr-Edwards aortic cloth covered valve, track valve, and silastic ball valve Eur. J. Cardiothorac. Surg., October 1, 1999; 16(4): 403 - 413. [Abstract] [Full Text] [PDF]

				C. Guglielmi, G. Toscano, V. Pistorio, I. Vendramin, T. Bottio, G. Thiene, and D. Casarotto Reoperations for acute prosthetic thrombosis and pannus: an assessment of rates, relationship and risk Eur. J. Cardiothorac. Surg., July 1, 1999; 16(1): 74 - 80. [Abstract] [Full Text] [PDF]